Resverlogix Corp.

Research Resverlogix Corp. (RVX) on Bullrun: market cap CAD 28.53M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerRVX
• ExchangeTO
• CountryCanada
• SectorHealthcare
• IndustryBiotechnology
• CurrencyCAD
• Market capCAD 28.53M
• Financial periodQ3 2025
• Net income-CAD 951.00K
• Free cash flow-CAD 913.00K

Valuation Snapshot

latest market cap is CAD 28.53M.

About Resverlogix Corp.

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions.

Frequently asked questions

What is Resverlogix Corp.'s market cap?

Resverlogix Corp.'s market capitalization is CAD 28.53M.

What does Resverlogix Corp. do?

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses.